Childhood vitiligo and tacrolimus: immunomodulating treatment for an autoimmune disease
- PMID: 12756103
- DOI: 10.1001/archderm.139.5.651
Childhood vitiligo and tacrolimus: immunomodulating treatment for an autoimmune disease
Comment on
-
A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo.Arch Dermatol. 2003 May;139(5):581-5. doi: 10.1001/archderm.139.5.581. Arch Dermatol. 2003. PMID: 12756094 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
